1. Home
  2. FTNT vs ARGX Comparison

FTNT vs ARGX Comparison

Compare FTNT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTNT
  • ARGX
  • Stock Information
  • Founded
  • FTNT 2000
  • ARGX 2008
  • Country
  • FTNT United States
  • ARGX Netherlands
  • Employees
  • FTNT N/A
  • ARGX N/A
  • Industry
  • FTNT Computer peripheral equipment
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FTNT Technology
  • ARGX Health Care
  • Exchange
  • FTNT Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • FTNT 61.5B
  • ARGX 51.1B
  • IPO Year
  • FTNT 2009
  • ARGX 2017
  • Fundamental
  • Price
  • FTNT $80.35
  • ARGX $917.87
  • Analyst Decision
  • FTNT Hold
  • ARGX Strong Buy
  • Analyst Count
  • FTNT 31
  • ARGX 17
  • Target Price
  • FTNT $90.74
  • ARGX $910.63
  • AVG Volume (30 Days)
  • FTNT 6.0M
  • ARGX 367.0K
  • Earning Date
  • FTNT 11-05-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • FTNT N/A
  • ARGX N/A
  • EPS Growth
  • FTNT 22.04
  • ARGX N/A
  • EPS
  • FTNT 2.43
  • ARGX 23.27
  • Revenue
  • FTNT $6,554,700,000.00
  • ARGX $3,683,281,000.00
  • Revenue This Year
  • FTNT $15.60
  • ARGX $85.93
  • Revenue Next Year
  • FTNT $11.60
  • ARGX $35.17
  • P/E Ratio
  • FTNT $33.15
  • ARGX $36.91
  • Revenue Growth
  • FTNT 14.78
  • ARGX 92.98
  • 52 Week Low
  • FTNT $70.12
  • ARGX $510.06
  • 52 Week High
  • FTNT $114.82
  • ARGX $934.13
  • Technical
  • Relative Strength Index (RSI)
  • FTNT 44.47
  • ARGX 70.28
  • Support Level
  • FTNT $77.17
  • ARGX $897.50
  • Resistance Level
  • FTNT $81.19
  • ARGX $932.29
  • Average True Range (ATR)
  • FTNT 2.21
  • ARGX 19.86
  • MACD
  • FTNT -0.17
  • ARGX -0.28
  • Stochastic Oscillator
  • FTNT 45.62
  • ARGX 82.07

About FTNT Fortinet Inc.

Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: